- Home
- PSF vs NERV Comparison
PSF vs NERV Comparison
Compare PSF & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PSF | NERV |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.8M | 269.6M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PSF | NERV |
|---|---|---|
| Price | $19.36 | $6.31 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 39.5K | ★ 320.5K |
| Earning Date | 01-01-0001 | 03-11-2026 |
| Dividend Yield | ★ 7.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.93 | $1.15 |
| 52 Week High | $21.20 | $12.46 |
Technical Indicators
Market Signals| Indicator | PSF | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 30.90 | 46.48 |
| Support Level | N/A | $5.34 |
| Resistance Level | $20.58 | $6.69 |
| Average True Range (ATR) | 0.18 | 0.69 |
| MACD | -0.03 | -0.24 |
| Stochastic Oscillator | 0.00 | 21.17 |
Price Performance
Historical ComparisonAbout PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.